Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trinity Technologies reintroducing generic drugs

Executive Summary

The Roseville, Michigan-based firm will have six generic drug products re-entering the market by January. The company voluntarily suspended manufacturing and distribution in August 1993 to address compliance problems, mainly related to process validation ("The Pink Sheet" Aug. 16, 1993, T&G-14). Trinity received additional capital for state-of-the-art manufacturing and processing equipment when it was acquired in March by Therapharm Holdings, Inc. Trinity expects to file several ANDAs in 1995 for long acting and narrow therapeutic range drugs
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS025500

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel